Skip to search formSkip to main contentSkip to account menu

CX 5461

Known as: CX5461, RNA Pol I Inhibitor CX5461, Pol I Inhibitor CX5461 
An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, CX-5461 selectively… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzothiazolesNaphthyridines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA…
Background: G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions within DNA. Our group has… 
2020
2020
A Multimodal Genotoxic Anticancer Drug Characterized by Pharmacogenetic Analysis in Caenorhabditis elegans
New anticancer therapeutics require extensive in vivo characterization to identify endogenous and exogenous factors affecting… 
2019
2019
Discovery of novel inhibitors of ribosome biogenesis by innovative high throughput screening strategies.
Over the past two decades ribosome biogenesis has emerged as an attractive target for cancer treatment. In this study, two high… 
2018
2018
Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.
Low aqueous solubility is a major barrier to the clinical application of otherwise promising drug candidates. We demonstrate that… 
2017
2017
Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered P54nrb and PSF to facilitate c-Myc translation
Altered expression of NEAT1, the architectural long non-coding RNA (lncRNA) of nuclear paraspeckles, has been reported during… 
2016
2016
Abstract 1319: A novel formulation of CX-5461, a small-molecule inhibitor of rRNA synthesis, and its use for treatment of acute myeloid leukemia models
CX-5461 is a RNA polymerase I inhibitor currently in Phase I clinical trial in Australia for patients with advanced hematologic… 
2015
2015
A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM).
e22212 Background: Ribosome biogenesis driven by RNA polymerase 1 (Pol1) is a fundamental cellular process increased in… 
Review
2014
Review
2014
Targeting the nucleolus for cancer-specific activation of p53.
2013
2013
Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies
Malignant transformation is commonly associated with dysregulated ribosome biogenesis and for more than 100 years, pathologists… 
2013
2013
Abstract B16: Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies
Malignant transformation is commonly associated with dysregulated ribosome biogenesis and for more than 100 years, pathologist… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)